Am J Psychiatry 155:36-42, January 1998
© 1998 American Psychiatric Association
Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
James C. Ballenger, M.D.,
David E. Wheadon, M.D.,
Martin Steiner, Ph.D.,
William Bushnell, M.S., and
Ivan P. Gergel, M.D.
OBJECTIVE: This study was designed to determine the minimum paroxetine dose effective for treating panic disorder. METHOD: Of 425 patients with DSM-III-R panic disorder with or without agoraphobia who underwent a 2-week drug-free screening period, 278 patients were randomly assigned to double-blind treatment with a 10-week course of placebo or paroxetine at a dose of 10, 20, or 40 mg/day. RESULTS: At 40 mg/day, paroxetine was superior to placebo across the majority of outcome measures. Despite a mean of 9.5 to 11.6 full panic attacks during the screening period, 86.0% of the patients taking 40 mg of paroxetine, 65.2% of those taking 20 mg, 67.4% of those taking 10 mg, and 50.0% of the placebo-treated patients were free of full panic attacks during the 2 weeks ending at week 10. The 40-mg paroxetine group experienced significantly greater global improvement than the placebo group and significantly greater improvement in frequency of full and limited-symptom panic attacks, intensity of full panic attacks, phobic fear, anxiety, and depressive symptoms, usually evident by week 4. All doses of paroxetine were well tolerated, and adverse effects were consistent with those associated with selective serotonin reuptake inhibitors. CONCLUSIONS: Paroxetine is an effective and well-tolerated short-term treatment of panic disorder. The minimum dose demonstrated to be significantly superior to placebo was 40 mg/day, although some patients did respond at lower doses. (Am J Psychiatry 1998; 155:36–42)
This article has been cited by other articles:
|
|
|
|
 
B. H. Levine and R. C. Albucher
Patient Management Exercise FOR PSYCHOPHARMACOLOGY
Focus,
September 1, 2006;
4(4):
496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
November 1, 2005;
19(6):
567 - 596.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Schruers and E. Griez
The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder
J Psychopharmacol,
December 1, 2004;
18(4):
553 - 558.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Rickels, R. Zaninelli, J. McCafferty, K. Bellew, M. Iyengar, and D. Sheehan
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
April 1, 2003;
160(4):
749 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Marshall, K. L. Beebe, M. Oldham, and R. Zaninelli
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Am J Psychiatry,
December 1, 2001;
158(12):
1982 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Otto, K. S. Tuby, R. A. Gould, R. Y.S. McLean, and M. H. Pollack
An Effect-Size Analysis of the Relative Efficacy and Tolerability of Serotonin Selective Reuptake Inhibitors for Panic Disorder
Am J Psychiatry,
December 1, 2001;
158(12):
1989 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. MICHELSON, C. ALLGULANDER, K. DANTENDORFER, A. KNEZEVIC, D. MAIERHOFER, V. MICEV, V. R. PAUNOVIC, I. TIMOTIJEVIC, N. SARKAR, L. SKOGLUND, et al.
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial
The British Journal of Psychiatry,
December 1, 2001;
179(6):
514 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Roy-Byrne, W. Katon, D. S. Cowley, and J. Russo
A Randomized Effectiveness Trial of Collaborative Care for Patients With Panic Disorder in Primary Care
Arch Gen Psychiatry,
September 1, 2001;
58(9):
869 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Gorman
A 28-Year-Old Woman With Panic Disorder
JAMA,
July 25, 2001;
286(4):
450 - 457.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Pollack, M. W. Otto, J. J. Worthington, G. G. Manfro, and R. Wolkow
Sertraline in the Treatment of Panic Disorder: A Flexible-Dose Multicenter Trial
Arch Gen Psychiatry,
November 1, 1998;
55(11):
1010 - 1016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goodnick and B. J. Goldstein
Selective serotonin reuptake inhibitors in affective disorders -- I. Basic pharmacology
J Psychopharmacol,
January 1, 1998;
12(4_suppl):
5 - S20.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. J. Goldstein and P. J Goodnick
Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics
J Psychopharmacol,
January 1, 1998;
12(4_suppl):
55 - S87.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Goodnick and B. J. Goldstein
Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life
J Psychopharmacol,
January 1, 1998;
12(4_suppl):
S21 - S54.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
